



## June 2023 Newsletter

### 2023 “Campaign for Cures” Research Goal and Request for Support

Dear Friend:

As you likely know by now, the John Paul II Medical Research Institute is looking to raise \$1 million as part of its 2023 “Campaign for Cures” initiative. Your support will enable us to advance medical research in our core therapeutic priority areas of neurodegenerative diseases, cancer, rare diseases, chronic diseases receptive to stem cell therapy and vaccine development. Please consider making a meaningful donation to help us meet this year’s fundraising goal and read how your support is making a difference in advancing ethical research in our search for better treatments and cures.

### More Robust Vaccine Technology to Combat Novel Respiratory Viruses

Now that three years have elapsed since the coronavirus pandemic surfaced, sufficient scientific data has exposed that mRNA vaccines that were developed and administered for COVID-19 came with significant medical risks and offered little protection against both infection and viral transmission. JP2MRI’s founder, Dr. Alan Moy, was one of the earliest physicians and scientists that publicly shared his concerns regarding these risks after evaluating data from prior vaccine developmental efforts globally. This medical opinion resulted in Dr. Moy’s statements being censored on social media platforms such as Facebook. Moreover, his medical privileges were threatened to be revoked by the Iowa Board of Medicine, which launched an investigation against Dr. Moy for alleged dissemination of misinformation (it should be noted that Dr. Moy’s prior conclusions are now generally accepted by public healthcare authorities). JP2MRI is pleased to report that the investigation against Dr. Moy was ultimately dismissed by the Board. Due to his initial concerns and a massive global request from the pro-life community, Dr. Moy elected to add vaccine developmental research as a therapeutic priority at JP2MRI, to help create a safer and more robust vaccine against novel respiratory viruses like coronavirus and influenza. For more details on Dr. Moy’s scientific reasoning and the Institute’s vaccine developmental efforts, please visit our Rumble video: (<https://rumble.com/v2lzy9m-john-paul-ii-medical-research-institutes-alan-moy-m.d.-on-the-misinfo-accus.html>) and/or view a detailed transcript of his public statement: ([https://www.jp2mri.org/\\_files/ugd/d8f730\\_4612bad4159747cbbbc42595e19be8ba.pdf](https://www.jp2mri.org/_files/ugd/d8f730_4612bad4159747cbbbc42595e19be8ba.pdf)).

### Neurodegenerative Disease Cell Therapy Update

JP2MRI has made significant progress in the past year in developing stem cells for neurodegenerative diseases including Alzheimer’s, Parkinson’s Disease, ALS, spinal cord injury and stroke. The Institute has created two separate platforms involving cell therapy. Several neurodegenerative diseases such as traumatic brain injury, Alzheimer’s disease, multiple sclerosis and stroke share common pathologies involving a local inflammatory insult which then results in progressive local neural cell injury and cell death. One of the Institute’s approaches to treating these diseases involves creating adult stem cells that have been genetically altered to deliver therapeutic peptides/proteins that are released by the stem cells to protect and repair damaged neural tissues. Our second approach, which applies to diseases such as Parkinson’s disease and spinal cord injury and where the damage is too advanced, involves using cell replacement to repair the damage. JP2MRI intends to use induced pluripotent stem cells (iPSC) we have generated for this cell replacement therapy. The Institute is currently developing universal cell therapy for cell transplantation diseases like Parkinson’s disease. This will eliminate the need for immunosuppressive drugs that lower the body’s immune system and make a patient more susceptible to side effects in order to avoid rejection. Since the last newsletter, JP2MRI has reduced our research costs by a factor of ten-fold.

### Cell Therapy for Treating Advanced Stages of Cancer

Medical therapies for treating advanced stages of solid organ cancer remains a challenge. Most cytotoxic chemotherapies are insufficient and carry significant adverse side effects. More recent cancer treatments have focused on small and large molecules that mediate more targeted molecular pathways in cancer. However, these targeted chemotherapies are often unable

to reduce the tumor burden. Since the Institute has now developed more expertise in stem cell research, JP2MRI is conducting research where stem cells can be used as an adjunctive treatment in combination with more targeted chemotherapy. There is growing evidence that adult stem cells that deliver biologics can increase cancer cell death (otherwise called apoptosis). The Institute is currently developing an adult stem cell that can be used for a variety of cancers which may be refractory to conventional treatment, and which occur in the liver, lung, pancreas, brain, kidney and breast. Additionally, the Institute is currently transforming iPSC into immune cells that specifically target cancer cells. These stem cells offer a potential targeted cell therapy with reduced side effects that could be used in combination with conventional chemotherapy to offer better outcomes for cancer patients.

**Cost of Research and Request for Support**

As you may expect, the costs associated with these research programs is very expensive and we need your continued support to ensure that we accomplish our research objectives. Your longstanding financial support has made the Institute the global leader in advancing ethical medical research to address unmet medical needs, regardless of one’s religious affiliation. The Institute provides regular updates on our research progress on our website ([jp2mri.org](http://jp2mri.org)) and on Facebook, Rumble.com and Gab.com. Thank you very much for your support.

Kind regards and God Bless,



Jay M. Kamath, J.D. / CEO  
John Paul II Medical Research Institute

2500 Crosspark Rd., Suite W230  
Coralville, IA 52241  
(office): 319-688-7367  
(fax): 319-887-2870  
[www.jp2mri.org](http://www.jp2mri.org)

---

**John Paul II Medical Research Institute Annual Support**

\$500      \$400      \$300      \$250      \$100      \$75      \$50      \$25      \$\_\_

Please provide phone and email address for the following:

- I would like to make a monthly contribution.
- I would like to sign up on the Patient Registry.
- I would like to sign up on the Physician Registry.
- I am a first-time donor: \_\_ Yes \_\_ No
- I would prefer to receive the newsletters by email.
- I / We have moved since the last newsletter. Our new address is \_\_\_\_\_.

**Please make checks out to: JP2MRI**

- Check
- Cash
- PayPal (Go to: [www.jp2mri.org](http://www.jp2mri.org))

**Date:** \_\_\_\_\_

Send to:  
JP2MRI  
2500 Crosspark Rd.  
Suite W230  
Coralville, IA 52241

**Phone:** \_\_\_\_\_ **Email:** \_\_\_\_\_

<<first>> <<last>>  
<<address>>  
<<city>>, <<st>>, <<zip>>